ALPCO Launches Antibodies Supporting Pancreatic Cancer Research
In response to recent reports that pancreatic cancer deaths are on the rise globally, ALPCO has released a line of pancreatic antibodies to provide the research community with reliable tools that can be used to better analyze and understand pancreatic cancer.
Salem, NH, July 29, 2014 --(PR.com)-- ALPCO has released a line of pancreatic antibodies in order to provide scientists with vital tools for advancing pancreatic cancer research. The new antibodies foster the differentiation and isolation of functionally distinct pancreatic cells through flow cytometry and immunohistochemistry applications.
Recent reports indicate that as of 2012, pancreatic cancer caused an estimated 330,000 deaths globally. Current projections show that pancreatic cancer will become the second-leading cause of cancer-related deaths in the U.S. by the year 2030. The research community is in need of reliable tools to analyze and understand the molecular mechanisms of pancreatic cancer to combat its steadily increasing growth.
“ALPCO is addressing these issues by now providing well characterized antibodies that can be used to advance pancreatic research,” says ALPCO’s President, Sean Conley.
Advancements have been made in regards to identifying extracellular markers specific to pancreatic cell subtypes, consisting of monoclonal antibodies that recognize the surface of endocrine, alpha, duct and acinar cells.
For more information about ALPCO’s new panel of pancreatic antibodies, visit http://www.alpco.com/products/Pancreatic_Antibodies.aspx
About ALPCO
ALPCO (American Laboratory Products Company) was founded in 1991 as a provider of immunoassay kits for the North American research markets. ALPCO’s mission is to offer unique product solutions that appeal to a diverse set of customer needs, while providing exceptional customer service and product support. http://www.alpco.com
Recent reports indicate that as of 2012, pancreatic cancer caused an estimated 330,000 deaths globally. Current projections show that pancreatic cancer will become the second-leading cause of cancer-related deaths in the U.S. by the year 2030. The research community is in need of reliable tools to analyze and understand the molecular mechanisms of pancreatic cancer to combat its steadily increasing growth.
“ALPCO is addressing these issues by now providing well characterized antibodies that can be used to advance pancreatic research,” says ALPCO’s President, Sean Conley.
Advancements have been made in regards to identifying extracellular markers specific to pancreatic cell subtypes, consisting of monoclonal antibodies that recognize the surface of endocrine, alpha, duct and acinar cells.
For more information about ALPCO’s new panel of pancreatic antibodies, visit http://www.alpco.com/products/Pancreatic_Antibodies.aspx
About ALPCO
ALPCO (American Laboratory Products Company) was founded in 1991 as a provider of immunoassay kits for the North American research markets. ALPCO’s mission is to offer unique product solutions that appeal to a diverse set of customer needs, while providing exceptional customer service and product support. http://www.alpco.com
Contact
ALPCO
Terance Fisher
1-800-592-5726
www.alpco.com
Terance Fisher
1-800-592-5726
www.alpco.com
Contact
Categories